Secarna Pharmaceuticals to Present at Upcoming Scientific Conferences
- Secarna to present at upcoming OTS Annual Meeting in Denver and SITC Annual Meeting in Phoenix
- Presentations highlight improved, AI-guided oligonucleotide platform as well as updates on lead program SECN-15
Martinsried (Munich), Germany, October 8, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, will present at the upcoming 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) and the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. Poster presentations will highlight novel findings expected to enhance the AI-powered prediction of oligonucleotide efficacy and safety by Oligofyer™, Secarna’s bioinformatics screening and selection module within its OligoCreator® platform, thereby supporting the identification and characterization of best-in-class oligonucleotide therapeutics. In addition, the Company will present updates on its lead program in development, SECN-15, an ASO targeting Neuropilin-1 (NRP1), a multifaceted target for cancer therapy.
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
- Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-
oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise
Martinsried (Munich), Germany, and Zurich, Switzerland, August 24, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.
Secarna Pharmaceuticals to present new preclinical and translational data on SECN-15 at ASCO 2026
- SECN-15, a potential first-in-class antisense oligonucleotide (ASO), constitutes promising new treatment option for solid tumors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting with the potential to overcome resistance to checkpoint inhibitors
Martinsried (Munich), Germany, May 27, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics will present new preclinical and translational data for its proprietary lead program SECN-15, an antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 in Chicago, IL, USA, on Saturday, May 30, 2026.
Would you like to keep up to date with the latest from Secarna Pharmaceuticals?
Click here to subscribe here to receive regular updates:
Latest News & Events
Secarna Pharmaceuticals to Present at Upcoming Scientific Conferences
- Secarna to present at upcoming OTS Annual Meeting in Denver and SITC Annual Meeting in Phoenix
- Presentations highlight improved, AI-guided oligonucleotide platform as well as updates on lead program SECN-15
Martinsried (Munich), Germany, October 8, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, will present at the upcoming 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) and the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. Poster presentations will highlight novel findings expected to enhance the AI-powered prediction of oligonucleotide efficacy and safety by Oligofyer™, Secarna’s bioinformatics screening and selection module within its OligoCreator® platform, thereby supporting the identification and characterization of best-in-class oligonucleotide therapeutics. In addition, the Company will present updates on its lead program in development, SECN-15, an ASO targeting Neuropilin-1 (NRP1), a multifaceted target for cancer therapy.
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
- Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-
oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise
Martinsried (Munich), Germany, and Zurich, Switzerland, August 24, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.
Secarna Pharmaceuticals to present new preclinical and translational data on SECN-15 at ASCO 2026
- SECN-15, a potential first-in-class antisense oligonucleotide (ASO), constitutes promising new treatment option for solid tumors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting with the potential to overcome resistance to checkpoint inhibitors
Martinsried (Munich), Germany, May 27, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics will present new preclinical and translational data for its proprietary lead program SECN-15, an antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 in Chicago, IL, USA, on Saturday, May 30, 2026.